<DOC>
	<DOCNO>NCT00312377</DOCNO>
	<brief_summary>This large phase III clinical study study effect vandetanib ( ZACTIMA ) treat non-small cell lung cancer ( NSCLC ) . Vandetanib new type agent target blood supply cancer tumour ( 's anti-vascular endothelial growth factor receptor ( VEGFR ) property ) tumour cell ( 's anti-endothelial growth factor receptor ( EGFR ) action ) . This study look effect vandetanib lung cancer patient cancer re-appear treatment standard chemotherapy . This clinical study test vandetanib anti-VEGF anti-EGFR characteristic deliver longer improve progression free survival improve overall survival docetaxel ( Taxotere ) alone . All patient participate clinical study receive treatment docetaxel , commonly use treatment recurrent non-small cell lung cancer . In addition , patient also receive vandetanib ( ZACTIMA ) , anti-EGFR / anti-VEGF agent . Recent clinical research show vascular endothelial growth factor receptor ( VEGFR ) inhibition , use standard chemotherapy , lead increase survival advanced non-small cell lung cancer ( NSCLC ) patient . Other research show epidermal growth factor receptor ( EGFR ) inhibitor , like erlotinib ( Tarceva ) also increase overall non-small cell lung cancer survival kill tumour cell stop dividing .</brief_summary>
	<brief_title>ZACTIMA ( Anti-EGFR / Anti-VEGF Agent ) Combined With Docetaxel Compared Docetaxel Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Lung cancer patient answer true follow statement eligible join clinical study . I confirm diagnosis locally advance metastatic non small cell lung cancer ( Stage IIIb IV ) I 1st line anticancer therapy . Previous treatment Avastin ( bevacizumab ) first line NSCLC allow . Lung cancer patient answer true follow NOT eligible join clinical study . I non small cell lung cancer ( NSCLC ) I receive treatment docetaxel ( Taxotere ) . Prior treatment paclitaxel acceptable . I receive 2nd line anticancer therapy ( For example , patient previous 2nd line non small cell lung cancer ( NSCLC ) treatment Tarceva ( erlotinib , OSI744 ) , Alimta ( pemetrexed ) eligible ) I treat VEGFRtyrosine kinase inhibitor ( TKIs ) ( sunitinib , sorafenib , VEGF TKIs ) . Previous treatment Avastin ( bevacizumab ) 1st line non small cell lung cancer permit . I history uncontrolled irregular heartbeat I history high blood pressure control medication If unsure mean inclusion exclusion criterion , please contact call center number help .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>